Savorite Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 28-11-2024
- Paid Up Capital ₹ 5.10 M
as on 28-11-2024
- Company Age 6 Year, 9 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 Cr
as on 28-11-2024
- Revenue 163.92%
(FY 2023)
- Profit 21.97%
(FY 2023)
- Ebitda -11084.19%
(FY 2023)
- Net Worth 82.90%
(FY 2023)
- Total Assets 107.56%
(FY 2023)
About Savorite Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.10 M.
The company currently has active open charges totaling ₹5.00 Cr.
Nandkishore Maheshwari and Vedant Maheshwari serve as directors at the Company.
- CIN/LLPIN
U33125GJ2019PTC105923
- Company No.
105923
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Savorite Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nandkishore Maheshwari  | Director | 07-Jan-2019 | Current |
| Vedant Maheshwari | Director | 07-Jan-2019 | Current |
Financial Performance of Savorite Pharmaceuticals.
Savorite Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 163.92% increase. The company also saw a substantial improvement in profitability, with a 21.97% increase in profit. The company's net worth Soared by an impressive increase of 82.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Savorite Pharmaceuticals?
In 2023, Savorite Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ronald Pharmaceuticals Private LimitedActive 31 years 8 monthsNandkishore Maheshwari and Vedant Maheshwari are mutual person
Mypher Pharmaceuticals LlpActive 10 years 3 monthsNandkishore Maheshwari and Vedant Maheshwari are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 22 Feb 2022 | ₹5.00 Cr | Open |
How Many Employees Work at Savorite Pharmaceuticals?
Savorite Pharmaceuticals has a workforce of 4 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Savorite Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Savorite Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
